Fsd/hsdd

https://academic.oup.com/jsm/article/21/Supplement_1/qdae001.225/7600627 Introduction Bremelanotide (Vyleesi) is an FDA-approved medication for the safe and efficacious treatment of hypoactive sexual desire disorder in premenopausal women, however, phase 3 trials revealed it improved arousal...

https://academic.oup.com/jsm/article/21/Supplement_1/qdae001.217/7600941 Abstract Introduction Bremelanotide is a centrally acting, cyclic heptapeptide analog of the neuropeptide α-melanocyte-stimulating hormone with elevated affinity for the melanocortin-4 receptor. Bremelanotide modulates...

An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder (2022) Sarah Cipriani, Chiara Alfaroli, Elisa Maseroli & Linda Vignozzi ABSTRACT Introduction: Female sexual response implies a deep intertwining between psychosocial and neurobiological...